BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15902620)

  • 1. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 2. Tyrosine kinases as targets for cancer therapy.
    Krause DS; Van Etten RA
    N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting protein kinases in cancer therapy.
    Fabbro D; García-Echeverría C
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
    Mross K
    Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.
    Dear R; Wilcken N; Shannon J
    Aust Fam Physician; 2008; 37(1-2):45-9. PubMed ID: 18239753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intensive search for agents that knock out tumor growth].
    Ostman A
    Lakartidningen; 2010 Apr 21-27; 107(16):1066-70. PubMed ID: 20476703
    [No Abstract]   [Full Text] [Related]  

  • 9. [New agents for solid tumours].
    Raida M
    Dtsch Med Wochenschr; 2006 Oct; 131(43):2407-10. PubMed ID: 17054057
    [No Abstract]   [Full Text] [Related]  

  • 10. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer].
    Leirdal M; Sioud M
    Tidsskr Nor Laegeforen; 2002 Jan; 122(2):178-82. PubMed ID: 11873574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiangiogenic therapy and p53.
    Browder T; Folkman J; Hahnfeldt P; Heymach J; Hlatky L; Kieran M; Rogers MS
    Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12143876
    [No Abstract]   [Full Text] [Related]  

  • 15. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 16. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 17. Growth factor receptors: implications in tumor biology.
    Srinivasan DM; Kapoor M; Kojima F; Crofford LJ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1246-9. PubMed ID: 16370390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
    Roussidis AE; Karamanos NK
    In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeting Ras related proteins for leukemia therapy].
    Kimura S; Maekawa T
    Rinsho Ketsueki; 2005 Mar; 46(3):179-86. PubMed ID: 16447712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.